Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the re-investment of dividends paid on July 8, 2010.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share purchase transactions:
- Ordinary Shares Purchase Price: £11.75 per share.
- ADR Purchase Price: $34.12 per ADR.
- Transaction Date: July 13, 2010.
Material Changes
The filing details an increase in shareholdings for various directors and connected persons following the dividend re-investment. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares and ADRs purchased by each listed director (e.g., Mr. J R Stéphenne purchased 594.80 Ordinary shares; Mr. J M Clarke purchased 401.99 Ordinary shares).
- Confirm the dividend payment date of July 8, 2010, and the subsequent reinvestment execution on July 13, 2010.
- Note that this filing does not contain operational or financial performance data for the period.